The European Patent Office has communicated its intention to grant Idogen’s Patent Application No. 11850142.8. The patent belongs to Idogen’s second patent family and covers Idogen’s technology for induction of IDO for treatment of autoimmune diseases and transplant rejection. A related application received “Notice of Allowance” in Japan in December 2016 and other applications are pending in Canada, the US and internationally. The granted patent will complement an earlier European Patent in Idogen’s first patent family, granted in December 2013. Final grant of this second patent by the EPO is expected to occur within two to three months following the completion of routine formalities by Idogen during the coming weeks.
CEO Lars Hedbys commented that ”This patent provides very important protection for our tolerogenic vaccine platform on the European market – a key market for us. The decision that the European Patent Office intends to grant the patent is very pleasing”.
For additional information about Idogen, please contact:
Lars Hedbys, CEO
Tel: +46 (0)46-275 63 30
This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 13th of January 2017.